Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the chemotherapy-induced anemia market grown in recent years?

The market for anemia induced by chemotherapy has seen substantial growth recently. Its progression is set to continue, increasing from $2.62 billion in 2024 to $2.82 billion in 2025, with a compound annual growth rate (CAGR) of 7.6%. The growth observed in the past is related to a rising number of cancer cases and chemotherapy procedures, an aging populace resulting in higher rates of cancer, the development and expansion of chemotherapy drugs and treatment plans, better survival rates for cancer overall, and heightened awareness and diagnosis of anemia as a possible side effect.

How is the chemotherapy-induced anemia market size expected to evolve during the forecast period?

Anticipated to experience robust growth in the upcoming years, the chemotherapy-induced anemia market is estimated to reach $3.81 billion by 2029, expanding at a compound annual growth rate (CAGR) of 7.9%. This growth during the forecast period is attributed to factors such as advancements in supportive cancer care, increasing healthcare expenditure and infrastructure, the application of personalized and targeted cancer therapies, incorporation of biomarker-driven treatment methods, and an intensified focus on early detection and intervention – complemented by the integration of digital health technologies in patient handling. Key trends projected for the forecast period encompass the creation of new chemotherapy drugs, integration of machine learning, progress in cancer research and treatment protocols, adoption of artificial intelligence, and collaborative efforts between pharmaceutical corporations and healthcare providers.

Get your chemotherapy-induced anemia market report here!

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report

Which key drivers are propelling the chemotherapy-induced anemia market’s growth?

The increase in cancer and anemia cases is expected to drive the growth of the chemotherapy-induced anemia market. Cancer is a condition that results in uncontrolled cell growth that can spread to different parts of the body. Individuals undergoing intense chemotherapy, with or without radiation treatment, often experience cancer and chemotherapy-induced anemia (CIA). The treatment aids in the production of red blood cells in the bone marrow, and is used to manage chemotherapy-induced anemia. As an example, according to Cancer Research UK, a UK-based independent research institution, the occurrence of head and neck cancer is expected to grow by 3% from 2023 to 2025, while fatalities due to these cancers are anticipated to rise by 12% during the same period. As a result, the rise in cancer and anemia rates fuels the expansion of the chemotherapy-induced anemia market.

What are the market segments in the chemotherapy-induced anemia industry?

The chemotherapy-induced anemia market covered in this report is segmented –

1) By Anemia: Mild Anemia, Moderate Anemia, Severe Anemia, Life-Threatening Anemia

2) By Treatment Type: RBC (Red Blood Cells) Transfusion, Erythropoiesis-Stimulating Agents (ESAs), Iron Supplementation

3) By End-User: Hospitals, Ambulatory Surgical Centers, Multispecialty Clinics, Cancer Research Centers, Cancer Rehabilitation Centers

Subsegments:

1) By Mild Anemia: Hemoglobin Levels 10-12 g/dL, Symptomatic Treatments

2) By Moderate Anemia: Hemoglobin Levels 8-10 g/dL, Erythropoiesis-stimulating Agents (ESAs), Blood Transfusion Management

3) By Severe Anemia: Hemoglobin Levels 6.5-8 g/dL, Intensive ESA Treatments, Frequent Blood Transfusions

4) By Life-Threatening Anemia: Hemoglobin Levels Below 6.5 g/dL, Emergency interventions, Critical Care And Monitoring

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12513&type=smp

Which leading companies are shaping the growth of the chemotherapy-induced anemia market?

Major companies operating in the chemotherapy-induced anemia market include Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Fresenius Kabi AG, Hospira Inc., Dr. Reddy’s Laboratories Ltd., Biocon Ltd., 3SBio Group, FibroGen Inc., Karger AG, Avesthagen Ltd., Blausen Medical Communications Inc., Aileron Therapeutics Inc.

What key trends are currently impacting the chemotherapy-induced anemia market’s development?

Leading corporations in the chemotherapy-induced anemia market are dedicating their efforts towards the invention of groundbreaking products such as biosimilars to augment the potency of treatments and curtail expenses. Biosimilars refer to biological medicinal items that bear a high resemblance to an already sanctioned reference biologic drug, without any considerable disparities in safety, purity, or efficiency. Their goal is to provide more cost-effective alternatives to high-priced biologic treatments while preserving equivalent therapeutic results. For example, in November 2022, Amneal Pharmaceuticals, Inc., a U.S. -based pharmaceutical firm, introduced RELEUKO (filgrastim-ayow). This product use Neupogen® as a reference and is primarily utilized for treating neutropenia, a usual condition faced by patients receiving chemotherapy and offers essential advantages to patients undergoing cancer treatment. It is chiefly designated to lower the occurrence of infections in patients who have febrile neutropenia from myelosuppressive chemotherapy, thereby improving their safety and recovery rate. Moreover, RELEUKO® assists in lessening the time taken for neutrophil recuperation and the duration of fever following chemotherapy for acute myeloid leukemia, and aids in alleviating the difficulties of neutropenia in patients undergoing a bone marrow transplant.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12513

Which geographic areas are influencing the growth of the chemotherapy-induced anemia market?

North America was the largest region in the chemotherapy-induced anemia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chemotherapy-induced anemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Clinical Oncology Next Generation Sequencing Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/clinical-oncology-next-generation-sequencing-global-market-report

Oncology Biosimilars Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Oncology Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/oncology-devices-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: